For the threat of substitute products, it is still very low due to patent protection, but in case of expired patents it is medium. A pharmaceutical company has many ways to counter generic drugs, such as obtaining patents on chemical components, manufacturing methods, product extensions/formula changes, or improving drug delivery methods. The rivalry between existing companies is medium. Every pharmaceutical company must fight to take advantage of the first to obtain patents. They also compete to get doctors' attention for their drugs by hiring representatives. There are several alternatives to make a company less venerable. For the bargaining power of customers, in the United States, MCOs are becoming stronger and stronger while the price battle against the buyer outside the United States does not decrease, so pharmaceutical companies cannot avoid reducing drug prices. A pharmaceutical company can move its research and development centers to... Strengths1. Low production cost.2. Large pool of installed capacity3. Efficient technologies for a large number of generic drugs.4. Large pool of qualified technical manpower.5. Increasing liberalization of government policies.Opportunities1. Aging of the world population.2. Growing incomes.3. Growing attention to health.4. New diagnoses and new social diseases.5. Spread prophylactic approaches.6. The market saturation point is far away.7. New therapeutic approaches.8. New delivery systems.9. Attitude of diffusion of soft drugs (over-the-counter drugs).10. Spread of the use of Generic Medicines.11. Globalization12. Easier international trade.13. New markets are opening up.Weakness1. Fragmentation of installed capacities.2. Low technological level of capital goods in this section.3. Unavailability of the main intermediaries for bulk drugs.4. Lack of experience to efficiently exploit the new patent regime.5. Very low level of research and development.6. India's low share in world pharmaceutical production (1.2% of world production but with 16.1% of world population).7. Very low level of biotechnology in India and also for new drug discovery systems.8. Lack of experience in international trade.9. Low level of strategic planning for the future and also technological foresight.Threats1. Containment of the increase in healthcare costs.2. High cost of discovering new products and fewer discoveries.3. More rigorous registration procedures.4. High entry costs into new markets.5. High cost of sales and marketing.6. Competition, especially from generic products.7. More potential new drugs and more effective therapies.8. Moving from Process Patent to Product Patent.Pharmaceutical and Healthcare Products India ReportIndependent five-year pharmaceutical and healthcare industry forecast for India.Original pharmaceutical and healthcare market research and trend analysis of pharmaceutical and healthcare industry for the pharmaceutical industry and Indian Healthcare. Competitive Intelligence, Indian Pharmaceutical and Healthcare Company Rankings and SWOT Analysis on National and International Pharmaceutical and Healthcare Companies in the Indian Market.